<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285476</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00468-31</org_study_id>
    <nct_id>NCT04285476</nct_id>
  </id_info>
  <brief_title>Predictive Value of 10 microRNA in Thyroid Cytologies of Undetermined Type</brief_title>
  <acronym>PREDICYTHY</acronym>
  <official_title>Study of the Predictive Value of a Signature of 10 microRNA in Thyroid Cytologies of Undetermined Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to validate a signature of 10 microRNA (micro Ribonucleic acid) selected in a
      first exploratory study allowing the stratification of the cytologies of indeterminate type
      (In a first step, the teams will focus on standardising the pre-analytical stages and
      defining a threshold of positivity. The results of microRNA signature on a cohort of 70
      patients will be compared with the ultrasound and then histological data of the resection
      specimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morphological analysis of fine-needle aspiration cytology (FNAC) under ultrasound classifies
      thyroid nodules in 6 categories (Bethesda classification). The diagnostic approach is
      codified by the Society of Endocrinology and for cytologies of indeterminate type (Bethesda
      3, 4 and 5), surgery of thyroid nodules is currently recommended. However, only 15.9% of the
      cytologies classified Bethesda 3, 26.1% of the Bethesda IV and 75.2% of the Bethesda V are
      actually cancers in the definitive histological analysis on surgical resection.

      Thus, new tools for predicting the risk of thyroid nodule malignancy need to be developed.

      To date, various risk stratification biomarkers have been reported in the literature but have
      not been validated in independent cohorts, thus excluding their implementation in daily
      practice.

      In addition, two commercial nucleic acid tests are proposed at a cost not compatible with
      generalized diffusion. The first approach is based on a next generation sequencing analysis
      of a target gene panel at the nucleotide sequence or transcribed level. The second
      alternative combines an analysis at level 1) of the deoxyribonucleic acid (DNA) with the
      search for somatic variations such as mutations in oncogenes or the presence of fusion genes,
      and 2) microRNA with the measurement of their level of expression.

      Due to their stability, their ability to modulate the expression of various messenger RNA,
      microRNA are an attractive line of research.

      The aim is to validate a signature of 10 microRNA selected in a first exploratory study
      allowing the stratification of the cytologies of indeterminate type (In a first step, the
      teams will focus on standardising the pre-analytical stages and defining a threshold of
      positivity. The results of microRNA signature on a cohort of 70 patients will be compared
      with the ultrasound and then histological data of the resection specimen.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under receiver operating characteristic (ROC) curve of the 10 microRNA signature</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the test (10 microRNA)</measure>
    <time_frame>24 months</time_frame>
    <description>Sensitivity is defined as the proportion of patients with a malignant nodule (diagnosed by the gold standard method) and a positive test with miRNA signature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of the test (10 microRNA)</measure>
    <time_frame>24 months</time_frame>
    <description>The specificity of the test is defined as the proportion of patients with a benign nodule (diagnosed by the gold standard method) and a negative test with miRNA signature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) of the test (10 microRNA)</measure>
    <time_frame>24 months</time_frame>
    <description>The positive predictive value is defined as the probability that the patient with a positive test is actually affected by a malignant nodule (diagnosed by the gold standard method).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV) of the test (10 microRNA)</measure>
    <time_frame>24 months</time_frame>
    <description>The negative predictive value is defined as the probability that the patient with a negative test is actually affected by a benign nodule (diagnosed by the gold standard method).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Signature of 10 microRNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Signature of 10 miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Signature of 10 microRNA for patients with bethesda classification 3, 4 or 5</intervention_name>
    <description>If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.</description>
    <arm_group_label>Signature of 10 microRNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman whose Age is ≥ 18 years

          2. Patient requiring ultrasound for thyroid nodule scanning with established indication
             of FNAC

          3. Patient with Bethesda 3, 4 and 5 thyroid nodule

          4. Informed patient and signed informed consent received

          5. Patient affiliated to a French medical coverage system

        Exclusion Criteria:

          1. Patient under guardianship, curatorship or safeguarding of justice

          2. Patient whose medical or psychological conditions do not permit them to complete the
             study or to sign the consent,

          3. Patient with metastatic cancer distinct from thyroid cancer

          4. Patient who has stopped treatment (chemotherapy / immunotherapy) for cancer for less
             than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Rivière, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du Cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse, MD</last_name>
    <phone>467613102</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédérique Savagner, MD</last_name>
      <phone>567690375</phone>
      <phone_ext>+33</phone_ext>
      <email>savagner.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chritine Rivière, MD</last_name>
      <phone>467618522</phone>
      <phone_ext>+33</phone_ext>
      <email>christine.riviere@icm.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Jacques C, Guillotin D, Fontaine JF, Franc B, Mirebeau-Prunier D, Fleury A, Malthiery Y, Savagner F. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors. J Clin Endocrinol Metab. 2013 May;98(5):E981-9. doi: 10.1210/jc.2012-4006. Epub 2013 Apr 8.</citation>
    <PMID>23569218</PMID>
  </results_reference>
  <results_reference>
    <citation>Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017 Sep;6(5):225-237. doi: 10.1159/000478927. Epub 2017 Aug 8.</citation>
    <PMID>29167761</PMID>
  </results_reference>
  <results_reference>
    <citation>Paschke R, Cantara S, Crescenzi A, Jarzab B, Musholt TJ, Sobrinho Simoes M. European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J. 2017 Jul;6(3):115-129. doi: 10.1159/000468519. Epub 2017 May 19.</citation>
    <PMID>28785538</PMID>
  </results_reference>
  <results_reference>
    <citation>Cantara S, Marzocchi C, Pilli T, Cardinale S, Forleo R, Castagna MG, Pacini F. Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. Int J Mol Sci. 2017 Apr 6;18(4). pii: E775. doi: 10.3390/ijms18040775. Review.</citation>
    <PMID>28383480</PMID>
  </results_reference>
  <results_reference>
    <citation>Sahli ZT, Smith PW, Umbricht CB, Zeiger MA. Preoperative Molecular Markers in Thyroid Nodules. Front Endocrinol (Lausanne). 2018 Apr 18;9:179. doi: 10.3389/fendo.2018.00179. eCollection 2018. Review.</citation>
    <PMID>29720964</PMID>
  </results_reference>
  <results_reference>
    <citation>Dedhia PH, Rubio GA, Cohen MS, Miller BS, Gauger PG, Hughes DT. Potential effects of molecular testing of indeterminate thyroid nodule fine needle aspiration biopsy on thyroidectomy volume. World J Surg. 2014 Mar;38(3):634-8. doi: 10.1007/s00268-013-2430-x.</citation>
    <PMID>24435929</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.</citation>
    <PMID>27078145</PMID>
  </results_reference>
  <results_reference>
    <citation>Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol. 2016 Mar;124(3):181-7. doi: 10.1002/cncy.21631. Epub 2015 Oct 12.</citation>
    <PMID>26457584</PMID>
  </results_reference>
  <results_reference>
    <citation>Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of &quot;Carcinomas&quot; Harboring RAS Mutations. Thyroid. 2017 Apr;27(4):506-511. doi: 10.1089/thy.2016.0583. Epub 2017 Feb 24.</citation>
    <PMID>28114855</PMID>
  </results_reference>
  <results_reference>
    <citation>Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories. Thyroid. 2015 Sep;25(9):987-92. doi: 10.1089/thy.2014.0612. Epub 2015 Jul 29.</citation>
    <PMID>26114752</PMID>
  </results_reference>
  <results_reference>
    <citation>Nabhan F, Porter K, Lupo MA, Randolph GW, Patel KN, Kloos RT. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2018 Jun;28(6):729-738. doi: 10.1089/thy.2017.0635. Epub 2018 May 16.</citation>
    <PMID>29665745</PMID>
  </results_reference>
  <results_reference>
    <citation>Finoux AL, Chartrand P. [Oncogenic and tumour suppressor microRNAs]. Med Sci (Paris). 2008 Dec;24(12):1049-54. doi: 10.1051/medsci/200824121049. Review. French.</citation>
    <PMID>19116113</PMID>
  </results_reference>
  <results_reference>
    <citation>Boufraqech M, Klubo-Gwiezdzinska J, Kebebew E. MicroRNAs in the thyroid. Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):603-619. doi: 10.1016/j.beem.2016.10.001. Epub 2016 Nov 1. Review.</citation>
    <PMID>27923454</PMID>
  </results_reference>
  <results_reference>
    <citation>Dom G, Frank S, Floor S, Kehagias P, Libert F, Hoang C, Andry G, Spinette A, Craciun L, de Saint Aubin N, Tresallet C, Tissier F, Savagner F, Majjaj S, Gutierrez-Roelens I, Marbaix E, Dumont JE, Maenhaut C. Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution. Oncotarget. 2017 Dec 8;9(12):10343-10359. doi: 10.18632/oncotarget.23130. eCollection 2018 Feb 13.</citation>
    <PMID>29535811</PMID>
  </results_reference>
  <results_reference>
    <citation>Titov SE, Demenkov PS, Ivanov MK, Malakhina ES, Poloz TL, Tsivlikova EV, Ganzha MS, Shevchenko SP, Gulyaeva LF, Kolesnikov NN. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. Oncol Rep. 2016 Nov;36(5):2501-2510. doi: 10.3892/or.2016.5113. Epub 2016 Sep 20.</citation>
    <PMID>27666315</PMID>
  </results_reference>
  <results_reference>
    <citation>Lithwick-Yanai G, Dromi N, Shtabsky A, Morgenstern S, Strenov Y, Feinmesser M, Kravtsov V, Leon ME, Hajdúch M, Ali SZ, VandenBussche CJ, Zhang X, Leider-Trejo L, Zubkov A, Vorobyov S, Kushnir M, Goren Y, Tabak S, Kadosh E, Benjamin H, Schnitzer-Perlman T, Marmor H, Motin M, Lebanony D, Kredo-Russo S, Mitchell H, Noller M, Smith A, Dattner O, Ashkenazi K, Sanden M, Berlin KA, Bar D, Meiri E. Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears. J Clin Pathol. 2017 Jun;70(6):500-507. doi: 10.1136/jclinpath-2016-204089. Epub 2016 Oct 26.</citation>
    <PMID>27798083</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

